These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29108214)

  • 1. [Association between intestinal flora imbalance and nonalcoholic fatty liver disease].
    Ma MJ; Wu J
    Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):789-793. PubMed ID: 29108214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.
    Koukias N; Buzzetti E; Tsochatzis EA
    Minerva Endocrinol; 2017 Jun; 42(2):184-194. PubMed ID: 27879962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
    Utzeri E; Usai P
    World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gut microbiota and nonalcoholic steatohepatitis].
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Ogawa Y; Yoneda M; Saito S; Nakajima A
    Nihon Yakurigaku Zasshi; 2018; 152(4):187-193. PubMed ID: 30298840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
    Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
    Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of gut microbial metabolites in nonalcoholic fatty liver disease.
    Zhao ZH; Lai JK; Qiao L; Fan JG
    J Dig Dis; 2019 Apr; 20(4):181-188. PubMed ID: 30706694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAFLD, Helicobacter species and the intestinal microbiome.
    Castaño-Rodríguez N; Mitchell HM; Kaakoush NO
    Best Pract Res Clin Gastroenterol; 2017 Dec; 31(6):657-668. PubMed ID: 29566909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of the gut-liver axis to the immune signaling pathway of NAFLD.
    Liu J; Wu A; Cai J; She ZG; Li H
    Front Immunol; 2022; 13():968799. PubMed ID: 36119048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.
    Cui Y; Wang Q; Chang R; Zhou X; Xu C
    J Agric Food Chem; 2019 Mar; 67(10):2754-2762. PubMed ID: 30798598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated bioinformatics analysis reveals potential mechanisms associated with intestinal flora intervention in nonalcoholic fatty liver disease.
    Liu Y; Liu X; Zhou W; Zhang J; Wu J; Guo S; Jia S; Wang H; Li J; Tan Y
    Medicine (Baltimore); 2022 Sep; 101(36):e30184. PubMed ID: 36086766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota: Association with NAFLD and Metabolic Disturbances.
    Lau E; Carvalho D; Freitas P
    Biomed Res Int; 2015; 2015():979515. PubMed ID: 26090468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of probiotics in treatment of nonalcoholic fatty liver disease].
    Chen M; Wang MC; Ni R; Wang J; Wang L; Wang GN; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Jan; 25(1):77-80. PubMed ID: 28297790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The regulatory effects of phytosterol esters (PSEs) on gut flora and faecal metabolites in rats with NAFLD.
    Song L; Li Y; Qu D; Ouyang P; Ding X; Wu P; Guan Q; Yang L
    Food Funct; 2020 Jan; 11(1):977-991. PubMed ID: 31803887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota, Obesity and NAFLD.
    Lau LHS; Wong SH
    Adv Exp Med Biol; 2018; 1061():111-125. PubMed ID: 29956210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.
    Federico A; Dallio M; Godos J; Loguercio C; Salomone F
    Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective.
    Wang L; Cao ZM; Zhang LL; Li JM; Lv WL
    Front Immunol; 2022; 13():923599. PubMed ID: 35911738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.